



COUNTY OF SAN LUIS OBISPO HEALTH AGENCY
PUBLIC HEALTH DEPARTMENT

Michael Hill Health Agency Director

Penny Borenstein, MD, MPH Health Officer/Public Health Director

PROVIDER HEALTH ADVISORY

Date: February 2, 2022

Contact: Rick Rosen, MD, MPH, 805-781-5500, frosen@co.slo.ca.us

Update: Access to COVID-19 Therapies in SLO County

As COVID-19 continues to surge in San Luis Obispo County, demand has increased for COVID-19 treatments while supply has remained very limited. The purpose of this advisory is to provide an update for health care providers on the local supply and referral processes for Sotrovimab, Paxlovid, Remdesivir, Molnupiravir, and Evusheld.

Sotrovimab

Sotrovimab supply to SLO County is limited but regular. Each week, the Public Health Department generally receives approximately 40 - 50 doses, which are distributed to participating health care providers. This includes SLO County hospitals (Arroyo Grande Community Hospital, French Hospital, Sierra Vista Regional Medical Center, Twin Cities Community Hospital), Community Health Centers of the Central Coast (CHC), and some independent providers, including Regenerative Mind Body (Dr. Timothy Jones).

Because supply is limited, health care providers are asked to provide this treatment only to patients in Tier 1 and Tier 2 of the [National Institutes of Health COVID-19 Treatment Guidelines for Patient Prioritization](#) (below). **Please ensure any patients you refer for this medication meet these current criteria.**

| Tier | Risk Group |
|------|--|
| 1 | <ul style="list-style-type: none"> Immunocompromised individuals not expected to mount an adequate immune response to COVID-19 vaccination or SARS-CoV-2 infection due to their underlying conditions, regardless of vaccine status (see Immunocompromising Conditions only to those in Tier 1 and Tier 2 of the NIH COVID-19 Treatment Guidelines Panel Criteria for Patient Prioritization for Outpatient Anti-SARS-CoV-2 Therapies below); or Unvaccinated individuals at the highest risk of severe disease (anyone aged ≥75 years or anyone aged ≥65 years with additional risk factors). |
| 2 | <ul style="list-style-type: none"> Unvaccinated individuals at risk of severe disease not included in Tier 1 (anyone aged ≥65 years or anyone aged <65 years with clinical risk factors) |

Public Health Department

2191 Johnson Avenue | San Luis Obispo, CA 93401 | (P) 805-781-5500 | (F) 805-781-5543

www.slopublichealth.org

Unfortunately, the large number of active cases and very limited supply of medication means even patients in these tiers may not be able to receive this medication immediately.

For more information, see the FDA Fact Sheet for Health Care Providers for Sotrovimab:
www.fda.gov/media/149534/download

Paxlovid

Paxlovid™ (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) is now available in extremely limited quantities in San Luis Obispo County. Several pharmacies are scheduled to receive small shipments (20-40 courses of treatment) from the California Department of Public Health (CDPH). Pharmacists and their staff are expected to review prescriptions for this medication to ensure they are appropriate given the EUA and current criteria.

Given the scarce supply, providers in SLO County are asked to prescribe Paxlovid only to patients in Tier 1 and Tier 2 of the [National Institutes of Health COVID-19 Treatment Guidelines for Patient Prioritization](#) (see detailed chart above).

A list of all pharmacies that will be receiving Paxlovid shipments is available from CDPH:
www.cdph.ca.gov/Programs/CID/DCDC/Pages/COVID-19/Antiviral-Therapeutics.aspx

The US Department of Health and Human Services (HHS) has also created a list of providers and pharmacies receiving shipments of Paxlovid, Molnupiravir, and Evusheld:
<https://healthdata.gov/Health/COVID-19-Public-Therapeutic-Locator/rxn6-qnx8/data>

Neither website represents availability, and providers should communicate with local pharmacies that will be receiving these drugs to ensure that supply exists before sending patients to pick up prescriptions.

For more information, see the FDA Fact Sheet for Healthcare Providers for Paxlovid:
www.fda.gov/media/155050/download

Veklury (remdesivir)

The FDA has recently expanded the EUA for remdesivir to include both adult and pediatric patients with certain health conditions that put them at risk of serious disease. It has also been expanded to allow administration in outpatient settings such as skilled nursing facilities, home healthcare settings and outpatient facilities such as infusion centers.

Providers may order remdesivir directly from the manufacturer; the Public Health Department is not involved in ordering. However, the Public Health Department is available to provide technical assistance to any local providers who wish to begin administering this medication to outpatients.

For more information, see the FDA Fact Sheet for Healthcare Providers for remdesivir:
www.fda.gov/media/137566/download

Molnupiravir

Molnupiravir has received emergency use authorization for people at high risk for severe illness for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate. This medication is not currently available in SLO County.

For more information, see the FDA Fact Sheet for Healthcare Providers for Molnupiravir: www.fda.gov/media/155054/download

Evusheld

Evusheld, a long-acting anti-SARS-COV-2 monoclonal antibody, is available for use as pre-exposure prophylaxis for COVID-19. Evusheld is authorized for those who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments AND may not mount an adequate immune response to COVID-19 vaccination; OR for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of a severe adverse reaction to a COVID-19 vaccine and/or COVID-19 vaccine component.

Evusheld is not approved for the management of individuals in isolation for COVID-19, nor for those in quarantine due to a recent exposure. Evusheld should not be considered a replacement for vaccination; COVID-19 vaccines provide more effective protection from COVID-19 for most individuals.

The supply of Evusheld in SLO County is currently adequate and regular. It is available to SLO residents via referral from healthcare providers only. To refer a patient for Evusheld, please contact:

- Wilshire Health & Community Services: Kahlua Sievert, 800-870-5920, ksievert@wilshirehcs.org
- Dr. Barry Eibschutz: 805-781-0702
- Dr. Thomas Spillane: (805) 543-5577

FDA Fact Sheet for Healthcare Providers: Emergency Use Authorization for Evusheld: <https://www.fda.gov/media/154701/download>

Stay informed

For updates on COVID-19 treatments in SLO County, visit slopublichealth.org/covid19.